Ernest Moles
Dr. Ernest Moles is a multidisciplinary investigator with extensive expertise in the fields of precision-nanomedicine, immunotherapy and oncology. Through his research at IBEC (Spain, 2010-2017), he developed >20 antibody-nanoparticle conjugates for management of difficult-to-treat paediatric blood diseases. Findings resulted in 12 publications at highly-regarded nanomedicine journals (J.Control Release-2015/2016,Biomaterials-2017; 50% as first or corresponding author). His research has influenced others to develop nanomaterials against HIV and cancer (Biomolec Chemistry,2020,18,9639-9652, Acta Pharmacologica Sinica,2021,42:1516-1523). Dr. Moles joined CCI in 2017, applying his translational capacity to engineer targeted nanotherapeutics for the treatment of high-risk cancers. Through UNSW-RIS 2019/2020 infrastructure funds ($923k), he established nanomedicine-dedicated infrastructure, the first of its kind at CCI/UNSW, through which he developed advanced chemo- & RNA-based lipid nanotherapeutics for the treatment of aggressive leukaemia (Pharmaceutics,2021,13:1681, Sci Transl Med,2023,15:eabm1262) and paediatric brain cancers (ongoing studies on DIPG & GBM through RNA Institute seed grant and Moderna Global programme). Contributions within the nanomedicine field are further evidenced by being cited in reviews of highly-regarded journals (Adv Drug Delivery Reviews,2020,154-155:151-162, Nature Nanotechnology,2021,16:369-384), an invited editorial contribution to Nature Biomedical Engineering (2019,3:248-250). Leadership in his field is further evidenced by the award of a prestigious US Moderna Global Fellowship (2023-25).
Abstracts this author is presenting: